Krelin (Pregabalin)

Pregabalin binds to the α2δ subunit of voltage‑gated calcium channels in the central nervous system. This reduces calcium entry into nerve terminals, limiting the release of excitatory neurotransmitters such as glutamate and norepinephrine, thereby decreasing neuronal over‑activity that contributes to pain, seizures, and anxiety.

The specific dose of Krelin is determined by the prescribing clinician based on the patient’s condition, severity, renal function, and response to therapy. Dosage may be adjusted over time, and patients should follow the prescriber’s instructions without self‑adjusting the amount.

Pregabalin is classified as a pregnancy category C medication, meaning risk cannot be ruled out. It should only be used if the potential benefit justifies the potential risk to the fetus. Breastfeeding is not recommended unless the benefit to the mother outweighs possible infant exposure, and a healthcare professional should be consulted.

To place an order, submit an enquiry on the Krelin product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Krelin (pregabalin) belongs to the gabapentinoid class, offering a different mechanism from tricyclic antidepressants or opioids. It is generally well‑tolerated and does not carry the same risk of dependence as opioids, but it may cause dizziness or edema. Choice of therapy depends on individual patient factors, efficacy, tolerability, and comorbid conditions.

Krelin tablets should be stored at temperatures below 25 °C, in their original packaging, protected from moisture and direct sunlight. Do not store in bathrooms or near heat sources, and keep out of reach of children.

Krelin is taken orally, usually with or without food, as directed by the prescriber. Tablets should be swallowed whole with a glass of water. The dosing schedule (once, twice, or thrice daily) is individualized based on therapeutic response and tolerability.

Serious risks include angioedema (rapid swelling of the face, lips, tongue, or throat), severe skin reactions such as Stevens‑Johnson syndrome, suicidal thoughts or behavior, and respiratory depression when combined with other central nervous system depressants. Patients should seek immediate medical attention if any of these symptoms occur.

Krelin is contraindicated in patients with known hypersensitivity to pregabalin or any of the tablet’s excipients. Caution is advised for individuals with severe renal impairment, uncontrolled heart failure, or those taking medications that may cause dangerous additive CNS depression.